CNDAC (hydrochloride)

CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis[1][2].

Product Specifications

CAS Number

[134665-72-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; DNA/RNA Synthesis; Drug Metabolite; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cndac-hydrochloride.html

Purity

98.01

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(N=C(N)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2.Cl

Molecular Formula

C10H13ClN4O4

Molecular Weight

288.69

Precautions

H302, H315, H319

References & Citations

[1]Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug;31 (8) :373-80.|[2]Jagan S, et al. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Adv Hematol. 2012;2012:727683.|[3]Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97 (5) :628-36.|[4]Azuma A, et al. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 1993 Dec 24;36 (26) :4183-9.